GUARDANT HEALTH INC
NASDAQ: GH (Guardant Health, Inc.)
Last update: 23 hours ago31.67
0.54 (1.73%)
| Previous Close | 31.13 |
| Open | 30.69 |
| Volume | 2,088,660 |
| Avg. Volume (3M) | 1,770,053 |
| Market Cap | 3,912,986,880 |
| Price / Sales | 5.67 |
| Price / Book | 55.67 |
| 52 Weeks Range | |
| Earnings Date | 20 Feb 2025 - 24 Feb 2025 |
| Profit Margin | -74.02% |
| Operating Margin (TTM) | -61.10% |
| Diluted EPS (TTM) | -4.28 |
| Quarterly Revenue Growth (YOY) | 33.90% |
| Current Ratio (MRQ) | 6.22 |
| Operating Cash Flow (TTM) | -254.07 M |
| Levered Free Cash Flow (TTM) | -151.07 M |
| Return on Assets (TTM) | -16.08% |
| Return on Equity (TTM) | -609.28% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | Guardant Health, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -1.13 |
|
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| % Held by Insiders | 4.57% |
| % Held by Institutions | 105.64% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Cadian Capital Management, Lp | 30 Sep 2024 | 6,930,474 |
| Parkwood Llc | 30 Sep 2024 | 2,800,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 50.00 (JP Morgan, 57.88%) | Buy |
| 50.00 (Leerink Partners, 57.88%) | Buy | |
| Median | 43.00 (35.78%) | |
| Low | 35.00 (Bernstein, 10.52%) | Buy |
| Average | 42.75 (34.99%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 25.23 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Goldman Sachs | 07 Nov 2024 | 36.00 (13.67%) | Buy | 28.59 |
| JP Morgan | 07 Nov 2024 | 50.00 (57.88%) | Buy | 28.59 |
| Bernstein | 30 Oct 2024 | 35.00 (10.51%) | Buy | 23.07 |
| Leerink Partners | 17 Oct 2024 | 50.00 (57.88%) | Buy | 20.68 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |